Time To Focus On GMP Activities Deferred By Pandemic, CDER Compliance Director Says
Executive Summary
US FDA’s Donald Ashley recaps the past year’s precedent-setting responses to the COVID-19 pandemic in Pink Sheet interview, while outlining a return to pre-COVID priorities and traditional inspection-based oversight.
You may also be interested in...
Pre-work Rigor, 'Clean' Documentation Are Key As US FDA Unlocks Remote Inspection Tools
A senior Parexel executive and ex-FDA pharmaceutical quality assessor emphasizes at a conclave why “first impressions matter now more than ever” as the agency deploys complex alternate inspections tools which the pandemic provided, and that companies need to ensure that they get things right the first time.
Pre-work Rigour, 'Clean' Documentation Key As FDA Unlocks Remote Inspection Tools
A senior Parexel executive and ex-FDA pharmaceutical quality assessor emphasizes at a conclave why “first impressions matter now more than ever” as the agency deploys complex alternate inspections tools which the pandemic provided, and that companies need to ensure that they get things right the first time.
The Quality Lowdown: Wishing Wished-For FDA Re-Inspections Had Gone Better?
As the COVID-19 pandemic wore on, industry clamored for the US FDA to re-inspect troubled drug manufacturing plants remotely if need be to clear them for new approvals. Now FDA investigators are out in force and early returns from Sun, Aurobindo, Lupin and Sterling suggest these re-inspections will be as tough as ever.